Hypertension is the most common chronic disease in the world. However, the exact cause of high blood pressure is often unknown. Animal models are particularly important in determining the pathogenesis of hypertension and in testing new therapeutic strategies. The aim of the study was to create a less invasive and cost-effective animal model of hypertension. To model arterial hypertension, experiments were carried out on white Wister rats weighing 200.0-250.0 g. Animals were randomly divided into 2 groups. Group I - control group (n=10), and II experimental group - 25mg/kg DOCA intraperitonially + 1% NaCl + 0.2% KCl in drinking water for 4 weeks. To assess the development of arterial hypertension, hemodynamic parameters, such as systolic and diastolic blood pressure, as well as heart rate, were measured twice a week using the “tail-cuff” method. Morphometric and morphological parameters of the heart were evaluated using electron microscopy of preparations stained with hematoxylin/eosin and Masson-trichrome. Systolic (163.6 ± 15 mmHg) and diastolic (77.9 ± 8 mmHg) blood pressure, as well as heart rate (438.5 ± 25 beats/min), was significantly increased by DOCA injection compared to control animals - 123.0 ± 5 mmHg p<0.05, 60.4 ± 3.0 mmHg p<0.05 and 361.4 ± 24 beats/min p<0.05, respectively. In hypertensive animals, hemodynamic changes were accompanied by blood test changes - ET-1 (41.6 ± 14 pg/ml), TNF-alpha (46.8 ± 17 pg/ml), IL-1 (8.6 ± 1.0 pg/ml) and increased levels of NF-kB (13.6 ± 4 pg/ml) compared to the control group (p<0.001). In correlation with blood pressure indicators, corresponding changes in the structure and tissue composition of the myocardium are recorded. Based on the obtained results, we can conclude that the use of DOCA and saline solutions with the proposed regimen allows for creation of a sustainable model of arterial hypertension. Compared to other DOCA-salt models of arterial hypertension, the advantage of this method is its technical simplicity and low cost.
Cai A, Calhoun DA. Resistant Hypertension: An Update of Experimental and Clinical Findings. Hypertension. 2017 Jul;70(1):5-9. doi: 10.1161/HYPERTENSIONAHA.117.08929. Epub 2017 May 15. PMID: 28507173; PMCID: PMC5515281.
Barrios V, Escobar C. Resistant hypertension. What is the best approach? Rev Esp Cardiol. 2009 Jun;62(6):711-2; author reply 712. English, Spanish. doi: 10.1016/s1885-5857(09)72244-3. PMID: 19480775.
Basting T, Lazartigues E. DOCA-Salt Hypertension: an Update. Curr Hypertens Rep. 2017 Apr;19(4):32. doi: 10.1007/ s11906-017-0731-4. PMID: 28353076; PMCID: PMC6402842.
Lerman LO, Kurtz TW, Touyz RM, Ellison DH, Chade AR, Crowley SD, Mattson DL, Mullins JJ, Osborn J, Eirin A, Reckelhoff JF, Iadecola C, Coffman TM. Animal Models of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2019 Jun;73(6):e87-e120. doi: 10.1161/HYP.0000000000000090. PMID: 30866654; PM- CID: PMC6740245.
Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the Immune System in Hypertension. Physiol Rev. 2017 Jul 1;97(3):1127-1164. doi: 10.1152/physrev.00031.2016. PMID: 28566539; PMCID: PMC6151499.
Lee WK, Padmanabhan S, Dominiczak AF. Genetics of hypertension: from experimental models to clinical applications. J Hum Hypertens. 2000 Oct-Nov;14(10-11):631-47. doi: 10.1038/sj.jhh.1001043. PMID: 11095156.
Graham D, McBride MW, Brain NJ, Dominiczak AF. Congenic/consomic models of hypertension. Methods Mol Med. 2005;108:3-15. doi: 10.1385/1-59259-850-1:003. PMID: 16028672.
Pestana-Oliveira N, Nahey DB, Johnson T, Collister JP. Development of the Deoxycorticosterone Acetate (DOCA)- salt Hypertensive Rat Model. Bio Protoc. 2020 Aug 5;10(15):e3708. doi: 10.21769/BioProtoc.3708. PMID: 33659372; PMCID: PMC7842531.
Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res. 1998 Jul;39(1):77-88. doi: 10.1016/s0008- 6363(98)00077-7. PMID: 9764191.
Bigiarelli KJ. Rodent Thermoregulation: Consider- ations for Tail-Cuff Blood Pressure Measurements. J Am Assoc Lab Anim Sci. 2022 Sep 1;61(5):406-411. doi: 10.30802/ AALAS-JAALAS-22-000006. Epub 2022 Aug 10. PMID: 35948400; PMCID: PMC9536829.
Shreenivas S, Oparil S. The role of endothelin-1 in human hypertension. Clin Hemorheol Microcirc. 2007;37(1- 2):157-78. PMID: 17641406.
Gomez-Sanchez EP. DOCA/Salt: Much More Than a Model of Hypertension. J Cardiovasc Pharmacol. 2019 Nov;74(5):369-371. doi: 10.1097/FJC.0000000000000753. PMID: 31599781.
Yemane H, Busauskas M, Burris SK, Knuepfer MM. Neurohumoral mechanisms in deoxycorticosterone acetate (DOCA)-salt hypertension in rats. Exp Physiol. 2010 Jan;95(1):51-5. doi: 10.1113/expphysiol.2008.046334. Epub 2009 Aug 21. PMID: 19700514.
Kandlikar SS, Fink GD. Mild DOCA-salt hyperten- sion: sympathetic system and role of renal nerves. Am J Physiol Heart Circ Physiol. 2011 May;300(5):H1781-7. doi: 10.1152/ajpheart.00972.2010. Epub 2011 Feb 25. PMID: 21357502; PMCID: PMC3094082.
Lilach O. Lerman, Theodore W. Kurtz, Rhian M. Touyz, Animal Models of Hypertension: A Scientific Statement from the American Heart Association, Hypertension. 2019; 73:e87– e120, doi.org/10.1161/HYP.0000000000000090
Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.J Exp Med. 2007; 204:2449–2460. doi: 10.1084/jem.20070657
Pestana-Oliveira N, Nahey DB, Johnson T, Collister JP. Development of the Deoxycorticosterone Acetate (DOCA)-salt Hypertensive Rat Model. Bio Protoc. 2020 Aug 5;10(15):e3708. doi: 10.21769/BioProtoc.3708. PMID: 33659372; PMCID: PMC7842531.